retatrutide mechanism retatrutide clinical trial A new weight-loss drug called is generating excitement after participants lost an average of 30% of their body weight, results that rival or even exceed weight-loss surgery. Researchers also retatrutide mechanism triple agonist glp-1

A patient may be a candidate for GLP-1 weight loss if they have obesity, overweight with weight-related health concerns, insulin resistance, prediabetes, type 2 diabetes risk, high blood pressure, high cholesterol, fatty liver concerns, sleep apnea risk, or repeated difficulty losing and maintaining weight with lifestyle changes alone

Clinical trials innovation, post-stroke risk, GLP-1 trends, and more In this issue, explore how Truveta is modernizing clinical trials with real-time design, optimization, and evidence generation using daily updated real-world data

doi: 10.1001/jamanetworkopen.2024.57349 114 ArvanitakisKKoufakisTPopovicDMalteseGMustafaODoumasMet al

Discussion The Ascend Blueprint's structured integration of protein-focused nutrition, resistance training, and routine tracking significantly mitigated muscle loss

It is simply newer information that has not yet made it into standard patient education materials

Funding information National Institutes of Health, Grant/Award Numbers: R01 DK119169, DK1191305830 DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author upon reasonable request